Shaker Investments LLC OH Sells 14,880 Shares of Immunomedics, Inc. (IMMU)

Shaker Investments LLC OH decreased its holdings in Immunomedics, Inc. (NASDAQ:IMMU) by 17.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 69,135 shares of the biopharmaceutical company’s stock after selling 14,880 shares during the quarter. Shaker Investments LLC OH’s holdings in Immunomedics were worth $1,440,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. BlackRock Inc. grew its position in Immunomedics by 24.3% in the second quarter. BlackRock Inc. now owns 11,228,828 shares of the biopharmaceutical company’s stock worth $265,786,000 after buying an additional 2,195,066 shares during the last quarter. FMR LLC grew its position in Immunomedics by 9.0% in the second quarter. FMR LLC now owns 8,494,182 shares of the biopharmaceutical company’s stock worth $201,057,000 after buying an additional 699,658 shares during the last quarter. Millennium Management LLC grew its position in Immunomedics by 37.4% in the second quarter. Millennium Management LLC now owns 3,742,519 shares of the biopharmaceutical company’s stock worth $88,585,000 after buying an additional 1,019,401 shares during the last quarter. Janus Henderson Group PLC grew its position in Immunomedics by 66.4% in the second quarter. Janus Henderson Group PLC now owns 3,217,759 shares of the biopharmaceutical company’s stock worth $76,164,000 after buying an additional 1,284,303 shares during the last quarter. Finally, RA Capital Management LLC acquired a new position in Immunomedics in the second quarter worth approximately $73,845,000. Hedge funds and other institutional investors own 78.19% of the company’s stock.

NASDAQ IMMU traded up $0.16 on Tuesday, hitting $22.04. 158,320 shares of the stock were exchanged, compared to its average volume of 1,930,171. Immunomedics, Inc. has a 52-week low of $8.68 and a 52-week high of $27.33. The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.83 and a current ratio of 14.83. The stock has a market cap of $4.20 billion, a price-to-earnings ratio of -21.41 and a beta of 1.85.

Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings data on Thursday, August 23rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). Immunomedics had a negative return on equity of 124.54% and a negative net margin of 12,701.21%. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $4.27 million. During the same quarter in the previous year, the firm posted ($0.48) earnings per share. The company’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, research analysts forecast that Immunomedics, Inc. will post -1.09 EPS for the current fiscal year.

Several research firms have issued reports on IMMU. BidaskClub lowered shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 26th. Goldman Sachs Group began coverage on shares of Immunomedics in a research report on Monday, September 17th. They issued a “buy” rating and a $36.00 price target on the stock. ValuEngine upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Wells Fargo & Co lifted their price target on shares of Immunomedics from $31.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Finally, Zacks Investment Research upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 29th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $38.00.

Immunomedics Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Recommended Story: Cash Flow

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply